title: Effects of famotidine on upper gastrointestinal motility in patients with progressive systemic sclerosis.
abstract: The effects of famotidine on human upper gastrointestinal motility were investigated, together with the relationship of gastric alkalinization and serum gastrin levels to changes produced by famotidine. Intravenous famotidine (20 mg), at a dose level in which an inhibitory effect on acetylcholinesterase activity is not recognized, was given to 13 patients with progressive systemic sclerosis but no other disorders. Gastric phasic motor activity was not changed significantly, but the lower esophageal sphincter pressure was elevated significantly in comparison with 15 controls given physiological saline, even when gastric phasic motor activity was taken into consideration. Gastric alkalinization with 7% sodium bicarbonate did not significantly increase the sphincter pressure in all 7 subjects so treated. No significant correlation was recognized between the serum gastrin level, the lower esophageal sphincter pressure, and the gastric motility index in any of the 3 groups. It was, therefore, concluded that intravenous administration of famotidine affected upper gastrointestinal motility, especially the lower esophageal sphincter pressure, through an as yet unknown mechanism other than inhibition of acetylcholinesterase activity, gastric alkalinization, or elevation of serum gastrin levels.
authors.affiliation: First Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Horikoshi
authors.forename: T
authors.initials: T
authors.lastname: Sekiguchi
authors.forename: M
authors.initials: M
authors.lastname: Kusano
authors.forename: T
authors.initials: T
authors.lastname: Matsuzaki
mesh_terms: D000328:Adult; D001639:Bicarbonates / Q000494:pharmacology; D016009:Chi-Square Distribution; D015738:Famotidine / Q000494:pharmacology*; D005260:Female; D005755:Gastrins / Q000097:blood*; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000097:blood / Q000503:physiopathology*; D012964:Sodium / Q000494:pharmacology; D017693:Sodium Bicarbonate; D013270:Stomach / Q000503:physiopathology*
chemical_list: D001639:Bicarbonates; D005755:Gastrins; D015738:Famotidine; D017693:Sodium Bicarbonate; D012964:Sodium